Document Actions
Gynecologic Cancer Steering Committee
As part of NCI’s restructuring of the clinical trials enterprise, the Gynecologic Cancer Steering Committee (GCSC) was transitioned into a NCI Disease-Site-Specific Group from the Gynecologic Cancer Intergroup in May of 2006. The GCSC will address, design, and prioritize phase 3 trials and evaluate randomized phase 2 trials in gynecologic cancer that leverage current Intergroup, Cooperative Group, Specialized Programs of Research Excellence (SPORE), and Cancer Center structures and involve the broad oncology and advocacy communities. The GCSC will function to harmonize an efficient, cost-effective, science-driven and transparent process that will identify and promote the “Best Science” in gynecologic cancer research. Members of the GCSC include Ccooperative Group gynecologic disease committee chairs, SPORE, Cancer Center and R01/P01 investigators along with community oncologists, a biostatistician, patient advocates, and NCI staff.
The GCSC is currently composed of the Steering Committee and three specific disease-site task forces (TF): Ovarian, Cervix and Uterine TFs. A major goal of the GCSC and its associated TFs is to increase the efficiency of clinical trial collaboration, reduce trial redundancy (phase 3 and phase 2), and increase information exchange at an early stage of trial development. The GCSC is responsible for the evaluation and prioritization of clinical trial concepts presented to the Committee by the TFs.
Each member of the GCSC is expected to regularly participate in the decision making activities of the Committee through monthly teleconferences and face-to-face meeting that will be held, when possible, in conjunction with national symposiums. Additionally, members of the GCSC and its associated TFs will plan and participate in State-of-the-Science Meetings.
The GCSC is currently composed of the Steering Committee and three specific disease-site task forces (TF): Ovarian, Cervix and Uterine TFs. A major goal of the GCSC and its associated TFs is to increase the efficiency of clinical trial collaboration, reduce trial redundancy (phase 3 and phase 2), and increase information exchange at an early stage of trial development. The GCSC is responsible for the evaluation and prioritization of clinical trial concepts presented to the Committee by the TFs.
Each member of the GCSC is expected to regularly participate in the decision making activities of the Committee through monthly teleconferences and face-to-face meeting that will be held, when possible, in conjunction with national symposiums. Additionally, members of the GCSC and its associated TFs will plan and participate in State-of-the-Science Meetings.
last modified
2007-11-08 09:28
